TimothyRWassenaarMD

Oncology • Waukesha, WI

Hematology at ProHealth Care/Regional Cancer Center

Join to view full profile

Dr. Wassenaar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wassenaar's full profile

Already have an account?

Office
N16W24131 Riverwood Dr
Waukesha, WI 53188
Phone+1 262-696-5690

Fax+1 262-696-0769

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2002 - 2005
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2002

Certifications & Licensure

WI State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE_NOT_RECRUITING
PHASE3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
ACTIVE_NOT_RECRUITING
PHASE3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
ACTIVE_NOT_RECRUITING
PHASE2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
ACTIVE_NOT_RECRUITING
PHASE3
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
COMPLETED
PHASE2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
ACTIVE_NOT_RECRUITING
PHASE2
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer Start of enrollment: 2013 Dec 01
Completed
Not Applicable
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
ACTIVE_NOT_RECRUITING
PHASE3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
COMPLETED
PHASE3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
ACTIVE_NOT_RECRUITING
PHASE3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
RECRUITING
PHASE2, PHASE3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
ACTIVE_NOT_RECRUITING
PHASE3
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
ACTIVE_NOT_RECRUITING
PHASE3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
ACTIVE_NOT_RECRUITING
PHASE2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
ACTIVE_NOT_RECRUITING
PHASE3
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma Start of enrollment: 2023 Dec 13
RECRUITING
PHASE3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana
Cancer Research Communications. 2023-07-01
13 citations
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Scott A Tomlins, Nickolay A Khazanov, Benjamin J Bulen, Daniel H Hovelson, Melissa J Shreve
Communications Medicine. 2023-02-07
2 citations
Barriers and facilitators to the use of survivorship care plans by hematopoietic stem cell transplant survivors and clinicians.
Colleen M. Morken, Amye J. Tevaarwerk, Mark B. Juckett, Amanda K. Swiecichowski, James E. Haine
Supportive Care in Cancer. 2021-09-05

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Timothy R. Wassenaar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Your Guide to the Top Doctors in the Milwaukee AreaJune 1st, 2022

TimothyRWassenaarMD

Dr. Wassenaar is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.